Clinical Trial Update: Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. [Phase 2]

View source ↗

Summary

Phase 2 trial of durvalumab with olaparib and fulvestrant in advanced ER-positive, HER2-negative breast cancer with BRCA or HRR alterations. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Fulvestrant (fulvestrant)
• Olaparib (Olaparib)

Snippet

Sponsor: UNICANCER | Conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status | Phase 2 | Status: ACTIVE_NOT_RECRUITING